Key result
Dabigatran achieves 0 thrombotic or bleeding events in a VKA-resistant LVAD patient post-stroke.
Why the study?
Does dabigatran etexilate prevent thrombotic or bleeding events in a patient with a HeartWare LVAD resistant to vitamin-K antagonists?
Case Report (n=1)
Does dabigatran etexilate prevent thrombotic or bleeding events in a patient with a HeartWare LVAD resistant to vitamin-K antagonists?
Dabigatran etexilate was used safely without thrombotic or bleeding events in an LVAD patient resistant to vitamin-K antagonists.
Answers are grounded in this paper and cite their sources.
May support dabigatran in VKA-resistant LVAD patients; leaves open need for prospective trials.
We report a case of a patient supported with a HeartWare left ventricular assist device for idiopathic cardiomyopathy who was resistance to vitamin-K antagonists three months after implantation. The patient initially started low-molecular-weight heparin therapy and then, after the onset of an ischemic stroke, switched to dabigatran etexilate (DE). The patient had progressive recovery of cardiac function for which the device was explanted. No thrombotic or bleeding events occurred during DE therapy.
No takes yet. Share an insight, caveat, or question.
Baronetto et al. (2017) conducted a case report in Idiopathic cardiomyopathy with HeartWare LVAD and vitamin-K antagonist resistance (n=1). Dabigatran etexilate was evaluated on Thrombotic or bleeding events. Dabigatran etexilate therapy resulted in 0 thrombotic or bleeding events in a HeartWare LVAD patient who was resistant to vitamin-K antagonists and had suffered an ischemic stroke.
Synapse has enriched 10 related papers. Consider them for comparative context: